Capsaicin 8% Patch vs Lidocaine 5% Patch for Neuropathic Pain
For neuropathic pain, capsaicin 8% patch is superior to lidocaine 5% patch based on stronger evidence and longer duration of action, providing pain relief for up to 12 weeks from a single 30-minute application compared to daily lidocaine applications.
Evidence-Based Comparison
Capsaicin 8% Patch: The Stronger Option
The 2017 HIVMA/IDSA guidelines provide a strong recommendation with high-quality evidence for capsaicin 8% patches in neuropathic pain 11. This represents the highest level of evidence available for topical treatments. Key advantages include:
- Single 30-minute application provides relief for at least 12 weeks 11
- Strong evidence across multiple neuropathic pain conditions: diabetic peripheral neuropathy, postherpetic neuralgia, HIV-associated neuropathy 2
- Minimal systemic absorption with localized action
- Number needed to treat (NNT) = 13.2 with excellent safety profile (NNH = 1129.3) 3
Lidocaine 5% Patch: Limited Evidence
Lidocaine 5% patches have very low certainty of evidence with an NNT of 14.5 3. The 2010 NCCN cancer pain guidelines mention lidocaine patches only as a general topical option without specific efficacy data 44. Key limitations:
- Requires daily application for 12-24 hours 5
- Evidence primarily limited to postherpetic neuralgia with allodynia 6
- Less effective for widespread or poorly localized pain
- More practical issues: patches must be applied directly over painful areas, limiting coverage
Clinical Application Algorithm
When to Choose Capsaicin 8%:
- First-line topical choice for well-localized neuropathic pain
- Diabetic peripheral neuropathy
- Postherpetic neuralgia
- HIV-associated peripheral neuropathy
- When patient compliance with daily applications is questionable
- When long-duration relief (3 months) is desired
When to Consider Lidocaine 5%:
- Postherpetic neuralgia specifically with allodynia 6
- Patients who cannot tolerate the initial burning from capsaicin
- As a pre-treatment before capsaicin: apply lidocaine 4% for 60 minutes, wipe off, then apply capsaicin to reduce initial burning 11
Critical Safety Considerations
Capsaicin 8% application causes predictable burning and erythema 11. This is not a treatment failure but an expected pharmacological effect:
- 54-58% of patients experience burning sensations 7
- Usually moderate to high intensity but lasting only 2 days on average 7
- Pre-treatment strategy: Apply lidocaine 4% for 60 minutes before capsaicin to minimize discomfort 11
Important pitfall: If the first capsaicin application fails, do not abandon treatment. Among patients who didn't improve after the first patch, 75% reported 50% improvement after the second application 7.
Practical Implementation
Capsaicin 8% Protocol:
- Pre-treat with lidocaine 4% for 60 minutes if concerned about burning
- Apply capsaicin 8% patch for 30 minutes to painful area
- Expect 2-3 days of burning (counsel patient this is normal)
- Pain relief begins within days and lasts 12 weeks
- If inadequate response, repeat application after 3 months
Lidocaine 5% Protocol:
- Apply up to 3 patches daily to affected areas
- Can be worn 12-24 hours
- Minimal systemic absorption
- Trial for at least 3-4 weeks before declaring failure 5
Evidence Hierarchy
The 2025 Lancet Neurology meta-analysis 3 and 2017 HIVMA/IDSA guidelines 11 represent the most recent, highest-quality evidence. Capsaicin 8% received a strong recommendation with high certainty of evidence, while lidocaine 5% received weak recommendation with very low certainty 3. This substantial difference in evidence quality should drive clinical decision-making.
The 2026 expert panel consensus 2 confirmed strong evidence for capsaicin 8% in diabetic peripheral neuropathy and postherpetic neuralgia, with only moderate evidence for lidocaine in these conditions.
Bottom line: Unless specifically treating postherpetic neuralgia with allodynia or the patient absolutely cannot tolerate initial burning despite lidocaine pre-treatment, capsaicin 8% patch is the evidence-based choice for localized neuropathic pain.